The Magazine for Sleep Professionals
Wednesday, April 22, 2026
ResMed today announced key upgrades to its Astral life support ventilators, including Optional AutoEPAP in iVAPS for U.S. patients, a high-demand therapy option. What is AutoEPAP? AutoEPAP (automatic expiratory positive airway pressure) automatically adjusts a patient’s expiratory pressure in response to flow limitations or obstruction of the upper airway. […]
Propeller Health’s digital medicines allow Anthem Blue Cross and Blue Shield consumers to better manage COPD symptoms Anthem Blue Cross and Blue Shield in Ohio announced the rollout of an innovative new program, with Propeller Health’s collaboration, to help improve health outcomes for Ohio consumers enrolled in Anthem’s Medicare Advantage […]
Masimo has announced the findings of a recently published study in which researchers investigated whether home pulse oximetry monitoring might be a useful initial screening method of determining which children with Down syndrome (DS) – who are at high risk of obstructive sleep apnea (OSA) – be recommended to undergo […]
Electromed, Inc. announced the results of an independent, outcome-based clinical study presented during the third annual World Bronchiectasis Conference in Washington D.C. The study’s findings reveal that early use of high-frequency chest wall oscillation (“HFCWO”) therapy with the SmartVest® Airway Clearance System significantly reduced severe exacerbations and hospitalizations among non-cystic […]
Wake Up Narcolepsy Awards Unrestricted Grants to Stanford And Harvard Narcolepsy Research At the SLEEP 2018 meeting held in early June, Wake Up Narcolepsy awarded Dr. Mignot from Stanford Center for Sleep Sciences and Medicine $45,000 for ongoing research. The funding allows Dr. Mignot to continue his pivotal research into […]
More than 4 in 10 women with asthma may go on to develop chronic obstructive pulmonary disease (COPD), according to a study conducted in Ontario, Canada, and published online in the Annals of the American Thoracic Society. In “Asthma and COPD Overlap in Women: Incidence and Risk Factors,” Teresa To, […]
Vertex Pharmaceuticals Incorporated announced the U.S. Food and Drug Administration (FDA) has approved ORKAMBI® (lumacaftor/ivacaftor) to include use in children ages 2 through 5 years with cystic fibrosis (CF) who have two copies of the F508del-CFTR mutation, making it the first medicine approved to treat the underlying cause of CF […]
Inhaled vaporized cannabis does not appear to improve or worsen exercise performance and activity-related breathlessness in patients with advanced chronic obstructive pulmonary disease (COPD), according to a randomized controlled trial published online in the Annals of the American Thoracic Society. In “Effect of Vaporized Cannabis on Exertional Breathlessness and Exercise […]
The American Thoracic Society led 10 medical professional organizations in filing an amicus brief last week regarding the FDA’s failure to apply pre-market review to new tobacco products. The brief was submitted in support of the American Academy of Pediatrics and its co-plaintiffs and outlines the compelling data indicating that the FDA’s failure to act […]
Higher daily doses of rifampin, a cornerstone of tuberculosis treatment, killed more TB bacteria in sputum cultures, and the higher doses did so without increasing the adverse effects of treatment, according to a randomized controlled trial published online in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine. In “Efficacy […]
